Marker Therapeutics (MRKR) Net Margin (2016 - 2025)
Marker Therapeutics (MRKR) posted quarterly Net Margin of 206.78% for Q4 2025, down 2180.0% year-over-year from 9.94% in Q4 2024, and down 27.56% quarter-over-quarter from 162.11% in Q3 2025.
Marker Therapeutics (MRKR) Net Margin (2016 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has reported Net Margin for 9 consecutive years, with 206.78% the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Margin fell 2180.0% year-over-year to 206.78%; the TTM figure through Dec 2025 stood at 372.74% (down 19402.0% YoY), while the FY2025 annual figure was 271.28%, down 10846.0% from the prior year.
- Net Margin slipped to 206.78% in Q4 2025 per MRKR's latest filing, from 162.11% in the prior quarter.
- Across five years, Net Margin topped out at 29.71% in Q1 2023 and bottomed at 1373.6% in Q1 2025.
- Historically, Net Margin has averaged 481.63% across 4 years, with a median of 206.78% in 2025.
- Annual changes were most pronounced in 2024 — Net Margin surged 114572 bps — and 2025, when it slumped 112338 bps.
- Marker Therapeutics' Net Margin stood at 107.1% in 2022, then slumped by 959 bps to 1134.45% in 2023, then surged by 84 bps to 184.99% in 2024, then fell by 12 bps to 206.78% in 2025.
- Business Quant data shows MRKR's Net Margin at 206.78% in Q4 2025, 162.11% in Q3 2025, and 481.2% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -206.78% |
| Sep 30, 2025 | -162.11% |
| Jun 30, 2025 | -481.20% |
| Mar 31, 2025 | -1,373.60% |
| Dec 31, 2024 | -184.99% |
| Sep 30, 2024 | -134.95% |
| Jun 30, 2024 | -169.33% |
| Mar 31, 2024 | -250.21% |
| Sep 30, 2023 | -1,134.45% |
| Jun 30, 2023 | -1,315.05% |
| Mar 31, 2023 | -29.71% |
| Dec 31, 2022 | -107.10% |
| Sep 30, 2022 | -119.34% |
| Jun 30, 2022 | -507.45% |
| Mar 31, 2022 | -1,048.16% |
| Dec 31, 2020 | -26,160.55% |
| Jun 30, 2020 | -4,037.55% |
| Dec 31, 2019 | -2,520.08% |
| Jun 30, 2018 | -2,268.90% |
| Sep 30, 2017 | -2,179.30% |